BSE filing, NSE: NATCOPHARM. Summary written from the filing by ALFA Finder's alert engine.
Natco Pharma Ltd: key numbers
- Share price
- ₹782.40
- Market cap
- ₹15,348 Cr
- Revenue (annual)
- ₹4,078 Cr
- Net profit (annual)
- ₹1,418 Cr
- P/E (TTM)
- 13.4×Sector 45.9×
- Promoter holding
- 49.39%-0.03% QoQ
- FII holding
- 15.99%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Natco Pharma Ltd
All →Natco Pharma Capital Structure Change
Natco Pharma allotted 5,86,666 equity shares to promoter Venkaiah Chowdary Nannapaneni via its rights issue, valued at ~₹44 Crore. This lifts his stake to 14.60%.
- Value
- ₹44.00 Cr
Natco Pharma Employee Stock Options
Natco Pharma's insiders, including promoters and directors, were allotted equity shares. This allotment increases their total shareholding in the company.
- Value
- ₹144.2 Cr
Natco Pharma Board Meeting Date
Natco Pharma will hold a board meeting on 13 November 2026 to consider unaudited quarterly results and an interim dividend. Trading window closed until 15 November 2026.
Natco Pharma Capital Structure Change
Natco Pharma's ₹1,279.4 Crore rights issue closed on October 22, 2026. Shares were priced at ₹750 each on a ₹2 face value.
- Value
- ₹1,279 Cr
Natco Pharma Product Launch
Natco Pharma launches Carboplatin Injection, a Paraplatin® generic, in the U.S. market via its subsidiary. The oncology product addresses a critical U.S. supply shortage.
Natco Pharma Other Announcement
Natco Pharma Ltd has submitted its quarterly shareholding pattern for the period ended September 30, 2026. This filing is a routine regulatory compliance submission.
Other management change announcements
All →NHPC Management Change
NHPC disclosed that Executive Director Shri Vivek Dwivedi's tenure ends on superannuation, effective October 31, 2026. The filing reports no replacement or financial impact.
BEML Management Change
BEML Limited informed exchanges that two senior executives, including the Executive Director (Offg.) Aparup Sinha, ceased office on superannuation effective 31 October 2026. No monetary value is involved.
Jay Jalaram Technologies Management Change
Jay Jalaram Technologies appointed Varjivandas Nathuram Thakkar as Non-Executive Non-Independent Director and Vishnu Harjivanbhai Thaker as Company Secretary. Both appointments are effective 31 October 2026.
Chennai Petroleum Corporation Management Change
Chennai Petroleum's Director (Operations) P. Kannan ceased on superannuation, effective 31 October 2026. S. G. Venkatesh takes additional charge from 1 November 2026.
GAMCO Management Change
GAMCO appointed Jayshri Tulsyan as Non-Executive Independent Director for 24 months, effective October 31, 2026. Ayushi Khaitan resigned as Non-Executive Non-Independent Director, citing personal reasons.
Dhampur Bio Organics Management Change
Dhampur Bio Organics' VP Financial Planning and Analysis, Harmeet Singh, resigned, effective October 31, 2026. It is a senior management departure.